(Reuters) – Johnson & Johnson said on Monday its Ebola vaccine regimen demonstrated antibody immune responses in adults and children, citing data published in the Lancet Infectious Diseases journal.
(Reporting by Shubham Kalia in Bengaluru; Editing by Anil D’Silva)
